GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2009

Neuraltus Closes $17M Series A Financing

Neuraltus Closes $17M Series A Financing

Neuraltus closes series A financing round with three firms

  • Neuraltus Pharmaceuticals completed a $17 million series A financing round with Latterell Venture Partners, VantagePoint Venture Partners, and Adam Street Partners. Each venture firm will have a seat on Neuraltus' board of directors.

    The funding is expected to cover the costs of Phase I and II testing for Neuraltus' ALS therapy, a treatment to reduce dyskinesia in Parkinson's patients, and a drug therapy for Gaucher's disease.

    "Neuraltus offers a strong pipeline of compounds for the treatment of serious neurological diseases for which there are few if any clinical options," says James Woody, Ph. D. of Latterell Venture Partners.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?